ReviewThe Lancet regional health. Europe2024
Recent achievements and future directions of anti-obesity medications.
Review in The Lancet regional health. Europe, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- [Anti-obesity drugs and potential changes in the epidemiology of this condition and in cardiovascular risk factors].Atencion primaria · 2026Article
- GIPR:GCGR co-agonism restores normal weight in obese rodents.Molecular metabolism · 2026Article
- Identification of a novel oral potential multiple agonist for obesity treatment: multi-target in silico study.Journal of computer-aided molecular design · 2026Article
- Incretin polyagonists as an alternative to bariatric surgery to manage obesity.World journal of gastrointestinal pathophysiology · 2026Review
- Advances in incretin-based drug discovery in 2025.Nature reviews. Endocrinology · 2026Article
- Obesity and Cancer: Mechanisms, Epidemiological Evidence, and Potential Risk Reduction.Journal of obesity & metabolic syndrome · 2026Review
- Application of nutrition interventions with GLP-1 based therapies: A narrative review of the challenges and solutions.Obesity pillars · 2025Review
- Targeting Progesterone Receptor Membrane Component 1 to Improve Muscle Development and Glucose Homeostasis.Journal of cachexia, sarcopenia and muscle · 2025Article
- Review
- Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders.Journal of neurology, neurosurgery, and psychiatry · 2025Review
- A derivative of the ancient drug salicylate for obesity treatment.Nature metabolism · 2025Article
- [Incretins as the basis of obesity treatment].Innere Medizin (Heidelberg, Germany) · 2025Review
- Effects of 17,18-Epoxyeicosatetraenoic Acid and 19,20-Epoxydocosapentaenoic Acid Combined with Soluble Epoxide Hydrolase InhibitorNutrients · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacological management of obesity long suffered from a reputation of a 'Mission Impossible,' with inefficient weight loss and/or unacceptable tolerability. However, the tide has turned with recent progress in biochemical engineering and the development of long-acting agonists at the receptor for glucagon-like peptide-1 (GLP-1), and with unimolecular peptides that simultaneously possess activity at the receptors for GLP-1, the glucose-dependent insulinotropic polypeptide (GIP) and glucagon. Some of these novel therapeutics not only improve body weight and glycemic control in individuals with obesity and type 2 diabetes with hitherto unmet efficacy and tolerable safety, but also exhibit potential therapeutic value in diverse areas such as neurodegenerative diseases, fatty liver disease, dyslipidemia, atherosclerosis, and cardiovascular diseases. In this review, we highlight recent advances in incretin-based therapies and discuss their pharmacological potential within and beyond the treatment of obesity and diabetes, as well as their limitations in use, side effects, and underlying molecular mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.